Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
View:
• Adult participants 19 years of age or older
• Participants who will be treated with luspatercept according to the approved label in the Republic of Korea
• Participants who sign the informed consent form
Locations
Other Locations
Republic of Korea
Local Institution - 0001
TERMINATED
Seoul
Novotech Laboratory Korea Co., Ltd.
RECRUITING
Seoul
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-03-25
Estimated Completion Date: 2027-12-21
Participants
Target number of participants: 104
Treatments
Participants with myelodysplastic syndrome or beta thalassemia who will begin luspatercept treatment
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb